| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 429,691 | 524,210 | ||
| General and administrative | 1,599,010 | 1,745,473 | ||
| Total operating expenses | 2,028,701 | 2,269,683 | ||
| Operating loss | -2,028,701 | -2,269,683 | ||
| Interest income | 35,911 | 23,404 | ||
| Net loss | -1,992,790 | -2,246,279 | ||
| Earnings per share, basic | -1.23 | -1.89 | ||
| Earnings per share, diluted | -1.23 | -1.89 | ||
| Weighted average number of shares outstanding, basic | 1,625,805 | 1,190,266 | ||
| Weighted average number of shares outstanding, diluted | 1,625,805 | 1,190,266 | ||
Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc. (ACXP)